Lifecome BiochemistryLtd Past Earnings Performance
Past criteria checks 0/6
Lifecome BiochemistryLtd's earnings have been declining at an average annual rate of -73%, while the Biotechs industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 12.4% per year.
Key information
-73.0%
Earnings growth rate
-72.8%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 12.4% |
| Return on equity | -80.2% |
| Net Margin | -43.5% |
| Next Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) Prospects Need A Boost To Lift Shares
Oct 04
Benign Growth For Lifecome Biochemistry Co.,Ltd. (SZSE:002868) Underpins Stock's 26% Plummet
Apr 21Lifecome Biochemistry Co.,Ltd. (SZSE:002868) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Mar 06Revenue & Expenses Breakdown
How Lifecome BiochemistryLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 603 | -262 | 69 | 34 |
| 31 Mar 24 | 567 | -243 | 63 | 30 |
| 31 Dec 23 | 507 | -222 | 55 | 28 |
| 30 Sep 23 | 493 | -140 | 44 | 23 |
| 30 Jun 23 | 416 | -132 | 41 | 23 |
| 31 Mar 23 | 367 | -123 | 44 | 22 |
| 01 Jan 23 | 330 | -122 | 40 | 22 |
| 30 Sep 22 | 345 | -88 | 39 | 23 |
| 30 Jun 22 | 334 | -69 | 39 | 25 |
| 31 Mar 22 | 335 | -37 | 36 | 24 |
| 31 Dec 21 | 363 | -26 | 38 | 25 |
| 30 Sep 21 | 319 | -6 | 28 | 23 |
| 30 Jun 21 | 304 | 14 | 27 | 22 |
| 31 Mar 21 | 317 | 32 | 28 | 22 |
| 31 Dec 20 | 308 | 43 | 29 | 20 |
| 30 Sep 20 | 324 | 65 | 38 | 21 |
| 30 Jun 20 | 338 | 67 | 38 | 21 |
| 31 Mar 20 | 318 | 59 | 37 | 18 |
| 31 Dec 19 | 304 | 57 | 35 | 19 |
| 30 Sep 19 | 311 | 50 | 34 | 19 |
| 30 Jun 19 | 320 | 59 | 34 | 17 |
| 31 Mar 19 | 323 | 67 | 35 | 15 |
| 31 Dec 18 | 344 | 75 | 35 | 15 |
| 30 Sep 18 | 341 | 74 | 32 | 14 |
| 30 Jun 18 | 357 | 80 | 27 | 20 |
| 31 Mar 18 | 368 | 78 | 30 | 18 |
| 31 Dec 17 | 375 | 86 | 34 | 14 |
| 30 Sep 17 | 383 | 84 | 38 | 11 |
| 30 Jun 17 | 364 | 79 | 46 | 0 |
| 31 Mar 17 | 383 | 88 | 47 | 0 |
| 31 Dec 16 | 401 | 92 | 48 | 0 |
| 31 Dec 15 | 386 | 78 | 46 | 0 |
| 31 Dec 14 | 296 | 31 | 38 | 0 |
| 31 Dec 13 | 297 | 33 | 41 | 0 |
Quality Earnings: 002868 is currently unprofitable.
Growing Profit Margin: 002868 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002868 is unprofitable, and losses have increased over the past 5 years at a rate of 73% per year.
Accelerating Growth: Unable to compare 002868's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002868 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (10.1%).
Return on Equity
High ROE: 002868 has a negative Return on Equity (-80.22%), as it is currently unprofitable.